Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort

Boehm, Katharina; Borgmann, Hendrik; Ebert, Thomas; Höfner, Thomas; Khaljani, Ehsan; Schmid, Marianne; Schulze-Seemann, W.; Weib, Peter; Herden, Jan

doi:10.1016/j.clgc.2020.12.004

Cited by 14 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, when limiting PSA tests, the potential for inverse stage migration for PCa is evident 5,6 . In a recent report by Boehm et al, 7 as well as within another report by Van den Bergh et al, 8 the continuing trend of inverse stage and grade migration in PCa patients was confirmed, not only in Germany, but also throughout Europe 7,8 . This trend might be—on the one hand—explained by efforts to reduce overtreatment in low‐risk PCa, but—on the other hand—might also be a worrisome indicator of deferred diagnosis and treatment, which may ultimately pose a detrimental effect on cancer‐specific outcomes.…”

Section: Introductionmentioning

confidence: 99%

Twenty‐year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort

et al. 2021

View full text Add to dashboard Cite

Background: A trend towards inverse stage migration in prostate cancer (PCa) was reported. However, previous analyses did not take into account potential differences in sampling strategies (number of biopsy cores), which might have confounded these reports.Material and Methods: Within our single-institutional database we identified PCa patients treated with radical prostatectomy (RP) between 2000 and 2020 (n = 21,646). We calculated the estimated annual percentage change (EAPC) for D'Amico risk groups, biopsy Gleason Grade Group (GGG), PSA and cT stage as well as postoperative RP GGG and pT stage relying on log linear regression methodology. Subsequently, we repeated the analyses after adjustment for number of cores obtained at biopsy. Results: Absolute rates of D'Amico low risk decreased (−30.1%), while intermediate and high risk increased (+21.2% and +9.0%, respectively). Rates of GGG I decreased (−50.0%), while GGG II-V increased, with the largest increase in GGG II (+22.5%). This trend, albeit less pronounced, was also recorded after adjusted EAPC analyses (p < .05). Specifically, EAPC values for D'Amico low vs intermediate vs high risk were −1.07%, +0.37%, +0.45%, respectively, and EAPC values for GGG ranged between −0.71% (GGG I) and +0.80% (GGG IV). Finally, an increase in ≥cT2 (EAPC: +3.16%) was displayed (all p < .001). These trends were confirmed in EAPC calculations in RP GGG and pT stages (p < .001). Conclusion:Our findings confirm the trend towards less frequent treatment of low risk PCa and more frequent treatment of high risk PCa, also after adjustment for number of biopsy cores.

show abstract